Biotech entity

Fosun Pharma

Company

Every one of those 1 sits in a single category, pharma. Fosun Pharma is most often covered alongside Gland Pharma, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.

Last mentioned: Mar 24, 2026

Entity pulse

Recent coverage · Fosun Pharma

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Fosun Pharma

Every one of those 1 sits in a single category, pharma. Fosun Pharma is most often covered alongside Gland Pharma, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Biotech story that mention Fosun Pharma, all published on March 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Fosun Pharma. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. 2025 Annual Results

    Fosun Pharma officially releases its full-year financial performance for 2025.

  2. US FDA Approval

    Key biosimilar assets receive final marketing authorization for the US market.

  3. CAR-T Expansion

    Yescarta receives expanded indication approval for second-line treatment in China.

  4. ADC Platform Milestone

    First internally developed ADC candidate enters Phase II clinical trials.

Stories mentioning Fosun Pharma 1

Pharma Neutral

Fosun Pharma 2025 Results: Innovation Revenue Surges as Global Footprint Expands

Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.

2 sources

Source: manilatimes.net · thailand-business-news.com

Fosun Pharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.